Research from the laboratory of Ari M. Melnick, M.D. has resulted in a promising new combinatorial therapy for diffuse large B cell lymphoma, an aggressive and rapidly progressive cancer that affects approximately 21,000 new people each year. This research, published in The Journal of Clinical Investigation, may hold significant implications for patient survival rates.
Ira M. Jacobson, M.D., the lead investigator of the ADVANCE trial, reported breakthrough findings at the 61st Annual Meeting of the American Association for the Study of Liver Disease in Boston on November 2, 2010. Adding a protease inhibitor – telaprevir – to the standard first-time treatment given to patients with hepatitis C resulted in a superior success rate.
Clinical studies at GHESKIO in Port-au-Prince, Haiti, have confirmed that early initiation of antiretroviral therapy significantly increases survival rates among HIV-1 patients. The study also links early intervention with a decreased rate of incident tuberculosis, a leading cause of death among HIV patients in resource-poor countries, according to the World Health Organization (WHO).
This award is presented annually to members of the Department of Medicine below the rank of professor who perform on outstanding levels in the areas of clinical and/or basic biomedical research. The award has been generously supported by the Michael Wolk Foundation.
The Fellows Research Award is presented annually to fellows within the Department of Medicine who have presented outstanding research.
Researchers from the Sackler Center at WCMC have designed a new class of drugs that targets a master regulatory protein responsible for causing the most common type of non-Hodgkin's lymphoma. Findings published April 14 in Cancer Cell show that an experimental compound designed by the researchers may effectively block the cancer-causing actions of the protein known as BCL6 by attaching to a critical "hot spot" on its surface, thus killing the cancer cells.
The National Institute on Aging (NIA) has awarded Weill Cornell Medical College a $2 million grant to fund an Edward R. Roybal Center for Research on Applied Gerontology, one of 12 such centers nationally. The grant will create the Cornell-Columbia Translational Research Institute on Pain in Later Life (TRIPLL), a collaboration focused on implementing innovative strategies for improving pain management among older adults.
Leading hematologists in the Department of Medicine presented new basic and clinical research findings at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans, Dec. 5-8.
African Americans constitute about 32 percent of all patients treated for kidney failure in the U.S. and are four times more likely to develop renal disease than whites, according to the National Institutes of Health's U.S. Renal Data System.
This award is presented annually to members of the Department of Medicine below the rank of professor who perform on outstanding levels in the areas of clinical and/or basic biomedical research. The award has been generously supported by the Michael Wolk Foundation.
